Edwards Lifesciences Q2 EPS of $0.58 Misses by 6.5%, Revenue Tops by 2%
Edwards Lifesciences reported fiscal Q2 adjusted EPS of $0.58, missing consensus by 6.5%, while revenues of $1.57 billion topped estimates by 2%. The company holds a Zacks Rank #2 Buy rating with a projected long-term earnings growth rate of 12.9% and has beaten forecasts in three of four trailing quarters.
1. Q2 Financial Results
Edwards Lifesciences reported fiscal second-quarter adjusted earnings per share of $0.58, missing consensus by 6.5%, while quarterly revenue reached $1.57 billion, topping estimates by 2%. The results reflect mixed performance across its cardiovascular and critical care segments.
2. Estimate Outlook and Rating
The company carries a Zacks Rank #2 Buy rating, supported by a projected long-term earnings growth rate of 12.9%, compared with a 14% industry average. This rating underscores analyst confidence in sustained demand for its heart valve and hemodynamic monitoring products.
3. Historical Earnings Performance
Edwards Lifesciences has beaten earnings estimates in three of the past four quarters with an average surprise of 5.5%. This consistency highlights the company’s ability to manage costs and capitalize on procedural volume growth across key markets.